GB0126902D0 - Organic compounds - Google Patents
Organic compoundsInfo
- Publication number
- GB0126902D0 GB0126902D0 GBGB0126902.6A GB0126902A GB0126902D0 GB 0126902 D0 GB0126902 D0 GB 0126902D0 GB 0126902 A GB0126902 A GB 0126902A GB 0126902 D0 GB0126902 D0 GB 0126902D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- treatment
- lower alkyl
- disease
- retinopathy
- age
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Priority Applications (29)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0126902.6A GB0126902D0 (en) | 2001-11-08 | 2001-11-08 | Organic compounds |
UA20040403226A UA77446C2 (en) | 2001-11-08 | 2002-07-11 | Anthranilic acid amides and their use as inhibitors of vegf receptor tyrosine kinase, process for their preparation, pharmaceutical composition |
SA02230412A SA02230412B1 (ar) | 2001-11-08 | 2002-11-02 | أميدات حمض الأنثرانيليك واستخدامها كمثبطاتanthranilic acid amides tyrosine kinase inhibitors لكيناز تيروسين المستقبل ل VEGF |
TW091132669A TWI260222B (en) | 2001-11-08 | 2002-11-06 | Anthranilic acid amides and pharmacological use thereof |
PE2002001080A PE20030714A1 (es) | 2001-11-08 | 2002-11-06 | Derivados de amidas de acido antranilico como inhibidores del receptor de tirosina quinasa vegf |
PL02368416A PL368416A1 (en) | 2001-11-08 | 2002-11-07 | Anthranilic acid amides and their use as vegf receptor tyrosine kinase inhibitors |
CNB028222091A CN1300113C (zh) | 2001-11-08 | 2002-11-07 | 邻氨基苯甲酰胺和其作为vegf受体酪氨酸激酶抑制剂的用途 |
JP2003542148A JP2005511602A (ja) | 2001-11-08 | 2002-11-07 | アントラニル酸アミドおよびvegf受容体チロシンキナーゼ阻害剤としてのその使用 |
DE60239073T DE60239073D1 (de) | 2001-11-08 | 2002-11-07 | Anthranilsäureamid derivate und deren verwendung als vegf-rezeptor tyrosin kinase inhibitoren |
ES02787595T ES2360283T3 (es) | 2001-11-08 | 2002-11-07 | Amidas de ácido antralínico y su uso como inhibidores de tirosina quisina receptora de vegf. |
MXPA04004391A MXPA04004391A (es) | 2001-11-08 | 2002-11-07 | Amidas de acido antranilico y su uso como inhibidores de tirosina-cinasa del receptor de vegf. |
NZ532590A NZ532590A (en) | 2001-11-08 | 2002-11-07 | Anthranilic acid amides and their use as VEGF receptor tyrosine kinase inhibitors |
PT02787595T PT1446382E (pt) | 2001-11-08 | 2002-11-07 | Amidas do ?cido antran?lico e sua utiliza??o como inibidores da tirosina quinase do receptor de vegf |
AT02787595T ATE496889T1 (de) | 2001-11-08 | 2002-11-07 | Anthranilsäureamid derivate und deren verwendung als vegf-rezeptor tyrosin kinase inhibitoren |
YU36004A YU36004A (sh) | 2001-11-08 | 2002-11-07 | Amidi antranilne kiseline i njihova upotreba kao receptora za vegf kojem je pridružena tirozinkinaza |
BR0213970-7A BR0213970A (pt) | 2001-11-08 | 2002-11-07 | Amidas de ácido antranìlico e uso farmacêutico dessas amidas |
US10/494,591 US7091224B2 (en) | 2001-11-08 | 2002-11-07 | Anthranilic acid amides and their use as VEGF receptor tyrosine kinase inhibitors |
AU2002351909A AU2002351909B2 (en) | 2001-11-08 | 2002-11-07 | Anthranilic acid amides and their use as VEGF receptor tyrosine kinase inhibitors |
RU2004117543/04A RU2318811C2 (ru) | 2001-11-08 | 2002-11-07 | Амиды антраниловой кислоты, способ их получения и их применение, способ лечения заболевания новообразованием и фармацевтический препарат, обладающий ингибирующей активностью в отношении тирозинкиназного рецептора vegf |
CA2463968A CA2463968C (en) | 2001-11-08 | 2002-11-07 | Anthranilic acid amides and their use as vegf receptor tyrosine kinase inhibitors |
KR1020047007040A KR100602977B1 (ko) | 2001-11-08 | 2002-11-07 | 안트라닐산 아미드 및 vegf 수용체 티로신 키나제억제제로서 그의 용도 |
EP02787595A EP1446382B1 (en) | 2001-11-08 | 2002-11-07 | Anthranilic acid amides and their use as vegf receptor tyrosine kinase inhibitors |
IL16174702A IL161747A0 (en) | 2001-11-08 | 2002-11-07 | Anthranilic acid amides and their use as vegf receptor tyrosine kinase inhibitors |
PCT/EP2002/012444 WO2003040102A1 (en) | 2001-11-08 | 2002-11-07 | Anthranilic acid amides and their use as vegf receptor tyrosine kinase inhibitors |
ZA200402940A ZA200402940B (en) | 2001-11-08 | 2004-04-19 | Anthranilic acid amides and their use as VEGF receptor tyrosine kinase inhibitors. |
HR20040411A HRP20040411A2 (en) | 2001-11-08 | 2004-05-07 | Anthranilic acid amides and their use as vegf receptor tyrosine kinase inhibitors |
CO04043909A CO5580823A2 (es) | 2001-11-08 | 2004-05-12 | Amidas de acido antranilico y su uso como inhibidores de tirosina-cinasa del receptor de vegf |
NO20042187A NO327231B1 (no) | 2001-11-08 | 2004-05-26 | Antranilsyreamider, farmasoytske preparat, anvendelser samt fremgangsmate for fremstilling |
US11/374,720 US7482369B2 (en) | 2001-11-08 | 2006-03-14 | Anthranilic acid amides and their use as VEGF receptor tyrosine kinase inhibitors |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0126902.6A GB0126902D0 (en) | 2001-11-08 | 2001-11-08 | Organic compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
GB0126902D0 true GB0126902D0 (en) | 2002-01-02 |
Family
ID=9925448
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GBGB0126902.6A Ceased GB0126902D0 (en) | 2001-11-08 | 2001-11-08 | Organic compounds |
Country Status (28)
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7307088B2 (en) * | 2002-07-09 | 2007-12-11 | Amgen Inc. | Substituted anthranilic amide derivatives and methods of use |
US7615565B2 (en) | 2002-07-31 | 2009-11-10 | Bayer Schering Pharma Aktiengesellschaft | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines |
GB0229022D0 (en) * | 2002-12-12 | 2003-01-15 | Novartis Ag | Organic Compounds |
DE10327719A1 (de) * | 2003-06-13 | 2005-01-20 | Schering Ag | VEGFR-2 und VEGFR-3 Inhibitorische Anthranylamidpyridone |
US7202260B2 (en) | 2003-06-13 | 2007-04-10 | Schering Ag | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridones |
US7129252B2 (en) * | 2003-06-16 | 2006-10-31 | Guoqing P Chen | Six membered amino-amide derivatives an angiogenisis inhibitors |
UA89035C2 (ru) | 2003-12-03 | 2009-12-25 | Лео Фарма А/С | Эфиры гидроксамовых кислот и их фармацевтическое применение |
EP1568368A1 (en) * | 2004-02-26 | 2005-08-31 | Schering Aktiengesellschaft | Pharmaceutical combination comprising a CDK inhibitor and a VEGF receptor inhibitor |
EP1657241A1 (en) | 2004-11-03 | 2006-05-17 | Schering Aktiengesellschaft | Novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors |
US7906533B2 (en) | 2004-11-03 | 2011-03-15 | Bayer Schering Pharma Ag | Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors |
EP1655295A1 (en) | 2004-11-03 | 2006-05-10 | Schering Aktiengesellschaft | Anthranilamide pyridinureas as VEGF receptor kinase inhibitors |
CN101094829B (zh) | 2004-12-07 | 2012-02-08 | 富山化学工业株式会社 | 新的氨茴酸衍生物或其盐 |
US7547782B2 (en) | 2005-09-30 | 2009-06-16 | Bristol-Myers Squibb Company | Met kinase inhibitors |
CN101265275B (zh) * | 2007-02-16 | 2012-09-05 | 中国医学科学院药物研究所 | 4-{6-[5-(2-氯-6-甲基苯胺甲酰基)-噻唑-2-氨基]-2-甲基嘧啶-4}-哌嗪-1-磷酸二乙酯 |
ES2445517T3 (es) | 2008-08-27 | 2014-03-03 | Leo Pharma A/S | Derivados de piridina como inhibidores de receptor VEGFR-2 y proteína tirosina cinasa |
JO3265B1 (ar) | 2008-12-09 | 2018-09-16 | Novartis Ag | مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض |
GB201322538D0 (en) | 2013-06-21 | 2014-02-05 | Immusmol Sas | Method for detecting small molecules in a sample |
CN107954893A (zh) * | 2017-11-28 | 2018-04-24 | 兰州纬寰生物科技有限公司 | 邻氨基苯甲酰胺衍生物及制备方法和用途 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9824579D0 (en) * | 1998-11-10 | 1999-01-06 | Novartis Ag | Organic compounds |
UA71587C2 (uk) * | 1998-11-10 | 2004-12-15 | Шерінг Акцієнгезелльшафт | Аміди антранілової кислоти та їхнє застосування як лікарських засобів |
-
2001
- 2001-11-08 GB GBGB0126902.6A patent/GB0126902D0/en not_active Ceased
-
2002
- 2002-07-11 UA UA20040403226A patent/UA77446C2/uk unknown
- 2002-11-02 SA SA02230412A patent/SA02230412B1/ar unknown
- 2002-11-06 TW TW091132669A patent/TWI260222B/zh active
- 2002-11-06 PE PE2002001080A patent/PE20030714A1/es not_active Application Discontinuation
- 2002-11-07 CN CNB028222091A patent/CN1300113C/zh not_active Expired - Fee Related
- 2002-11-07 PT PT02787595T patent/PT1446382E/pt unknown
- 2002-11-07 JP JP2003542148A patent/JP2005511602A/ja active Pending
- 2002-11-07 CA CA2463968A patent/CA2463968C/en not_active Expired - Fee Related
- 2002-11-07 WO PCT/EP2002/012444 patent/WO2003040102A1/en active IP Right Grant
- 2002-11-07 IL IL16174702A patent/IL161747A0/xx unknown
- 2002-11-07 BR BR0213970-7A patent/BR0213970A/pt not_active IP Right Cessation
- 2002-11-07 RU RU2004117543/04A patent/RU2318811C2/ru not_active IP Right Cessation
- 2002-11-07 NZ NZ532590A patent/NZ532590A/en not_active IP Right Cessation
- 2002-11-07 YU YU36004A patent/YU36004A/sh unknown
- 2002-11-07 EP EP02787595A patent/EP1446382B1/en not_active Expired - Lifetime
- 2002-11-07 US US10/494,591 patent/US7091224B2/en not_active Expired - Fee Related
- 2002-11-07 AU AU2002351909A patent/AU2002351909B2/en not_active Ceased
- 2002-11-07 DE DE60239073T patent/DE60239073D1/de not_active Expired - Lifetime
- 2002-11-07 AT AT02787595T patent/ATE496889T1/de active
- 2002-11-07 KR KR1020047007040A patent/KR100602977B1/ko not_active IP Right Cessation
- 2002-11-07 PL PL02368416A patent/PL368416A1/xx not_active Application Discontinuation
- 2002-11-07 MX MXPA04004391A patent/MXPA04004391A/es active IP Right Grant
- 2002-11-07 ES ES02787595T patent/ES2360283T3/es not_active Expired - Lifetime
-
2004
- 2004-04-19 ZA ZA200402940A patent/ZA200402940B/en unknown
- 2004-05-07 HR HR20040411A patent/HRP20040411A2/hr not_active Application Discontinuation
- 2004-05-12 CO CO04043909A patent/CO5580823A2/es not_active Application Discontinuation
- 2004-05-26 NO NO20042187A patent/NO327231B1/no not_active IP Right Cessation
-
2006
- 2006-03-14 US US11/374,720 patent/US7482369B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB0126902D0 (en) | Organic compounds | |
BRPI0116967B8 (pt) | derivado de pirazina ou um sal deste, composição farmacêutica, e, derivado de fluoropirazina ou um sal deste | |
MY141597A (en) | 2,4-disubstituted thiazolyl derivatives | |
MX2007000028A (es) | Derivados de nicotinamida y su uso como agentes terapeuticos. | |
MXPA01004256A (es) | N-arilamidas del acido antranilico y del acido tioantranilico. | |
NO20060113L (no) | Pyrrolo(3,4-c)pyrazolderivater aktive som kinase inhibitorer | |
UA91332C2 (uk) | Кристалічна малеатна сіль хіназоліну (варіанти), корисна як антиангіогенний агент | |
WO2005056524A3 (en) | Therapeutic agents useful for treating pain | |
GB0606805D0 (en) | Organic compounds | |
WO2005016867A3 (en) | Anthranilic acid derivatives and their use as activators of the hm74a receptor | |
ATE366107T1 (de) | Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen | |
MY136322A (en) | Anthranilic acid amides and pharmaceutical use thereof | |
NO971743D0 (no) | Farmasöytisk sammensetning for profylakse og behandling av type I allergiske sykdommer | |
ZA200105886B (en) | Agent of treating Parkinson's disease comprising astrocyte function-improving agent as active ingredient. | |
ATE440835T1 (de) | Heterozyklische harnstoff-derivate für die behandlung von schmerzen. | |
ATE428709T1 (de) | Anthranilsäureamide und ihre pharmazeutische verwendung | |
EP2266566A3 (en) | Nicotinamide derivatives and their use as therapeutic agents | |
HUP0301119A2 (hu) | Bioaktiváló hatóanyag és gyógyszerkészítmény | |
TH88080A (th) | แอนทรานิลิกแอซิดเอไมด์และการใช้งานทางเภสัชกรรมของมัน | |
TH88080B (th) | "แอนทรานิลิกแอซิดเอไมด์และการใช้งานทางเภสัชกรรมของมัน" | |
TH58670B (th) | อนุพันธ์ 2-อะมิโน-3-(แอลคิล)-พิริมิโดน | |
SI1553938T1 (sl) | Uporaba epotilonskih derivatov za zdravljenje hiperparatiroidizma | |
TH64488A (th) | แอนทรานิลิกแอซิดเอไมด์และการใช้งานทางเภสัชกรรมของมัน | |
UY27534A1 (es) | Amidas de ácido antranílico y uso farmacológico de las mismas. | |
TH66266A (th) | สารประกอบทางเคมี |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AT | Applications terminated before publication under section 16(1) |